
    
      Based on Good Post-marketing Study Practice (GPSP) regulation, general patient population
      with ischemic heart disease who are eligible for treatment with XIENCE Xpedition
      Everolimus-Eluting 2.25mm Stent will be registered, with no particular inclusion/exclusion
      criteria, and may be eligible for angiographic follow-up at eight months and clinical
      follow-up at one year.

      The XIENCE Xpedition 2.25 mm stent is composed of the stent identical to the stent of the
      XIENCE PRIME SV Stent.Therefore, the data collected from the PMS will be pooled with data
      collected from the ongoing XIENCE PRIME SV PMS for analysis.
    
  